Videos

Mark Kris, MD: Evaluating Therapeutic Options

April 26th 2016

Mark Kris, MD: Choosing a Treatment in NSCLC

April 26th 2016

Mark Kris, MD: Lacking Actionable Mutations in NSCLC

April 26th 2016

mCRC with Tanios Bekaii-Saab, MD and Tara Seery, MD: Case 2

April 26th 2016

mCRC with Tanios Bekaii-Saab, MD and Tara Seery, MD

Tanios Bekaii-Saab, MD; Chemotherapy as a Possible Option

April 26th 2016

Tara Seery, MD; Chemotherapy as a Possible Option

April 26th 2016

Tanios Bekaii-Saab, MD: KRAS Status in mCRC

April 26th 2016

Tara Seery, MD: KRAS Status in mCRC

April 26th 2016

Tanios Bekaii-Saab, MD: Impact of Third-Line Therapy

April 26th 2016

Tara Seery, MD: Impact of Third-Line Therapy

April 26th 2016

Tanios Bekaii-Saab, MD: Clinical Data Supporting Trifluradine-Tipiracil

April 26th 2016

Tara Seery, MD: Clinical Data Supporting Trifluradine-Tipiracil

April 26th 2016

Tanios Bekaii-Saab, MD: Fourth-Line Therapy in mCRC

April 26th 2016

Tara Seery, MD: Fourth-Line Therapy in mCRC

April 26th 2016

Charles Fuchs, MD: Cost Issues With CT Regimens and Bevacizumab

April 26th 2016

Charles Fuchs, MD: Strategies to Increase RAS Testing

April 26th 2016

Charles Fuchs, MD: Impeding RAS Mutation Testing

April 26th 2016

Charles Fuchs, MD: Percentage of RAS Mutation Tests in Metastatic CRC

April 26th 2016

Charles Fuchs, MD: RAS Mutations and the Sequence of Therapies

April 26th 2016

Charles Fuchs, MD: Clinical Importance of RAS Mutations

April 26th 2016

Charles Fuchs, MD: RAS Mutations in Metastatic Colorectal Cancer

April 26th 2016

Tanios Bekaii-Saab, MD: Cost Issues With CT Regimens and Bevacizumab

April 26th 2016

Tanios Bekaii-Saab, MD: Strategies to Increase RAS Testing

April 26th 2016

Tanios Bekaii-Saab, MD: Impeding RAS Mutation Testing

April 26th 2016

Tanios Bekaii-Saab, MD: Percentage of RAS Mutation Tests in Metastatic CRC

April 26th 2016

Tanios Bekaii-Saab, MD: RAS Mutations and the Sequence of Therapies

April 26th 2016

Tanios Bekaii-Saab, MD: Clinical Importance of RAS Mutations

April 26th 2016

Tanios Bekaii-Saab, MD: RAS Mutations in Metastatic Colorectal Cancer

April 26th 2016

Tanios Bekaii-Saab, MD: Mutations in Colorectal Cancer

April 26th 2016

Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD: Case 2

April 26th 2016

Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD

Videos

Mark Kris, MD: Evaluating Therapeutic Options

Mark Kris, MD: Choosing a Treatment in NSCLC

Mark Kris, MD: Lacking Actionable Mutations in NSCLC

mCRC with Tanios Bekaii-Saab, MD and Tara Seery, MD: Case 2

Tanios Bekaii-Saab, MD; Chemotherapy as a Possible Option

Tara Seery, MD; Chemotherapy as a Possible Option

Tanios Bekaii-Saab, MD: KRAS Status in mCRC

Tara Seery, MD: KRAS Status in mCRC

Tanios Bekaii-Saab, MD: Impact of Third-Line Therapy

Tara Seery, MD: Impact of Third-Line Therapy

Tanios Bekaii-Saab, MD: Clinical Data Supporting Trifluradine-Tipiracil

Tara Seery, MD: Clinical Data Supporting Trifluradine-Tipiracil

Tanios Bekaii-Saab, MD: Fourth-Line Therapy in mCRC

Tara Seery, MD: Fourth-Line Therapy in mCRC

Charles Fuchs, MD: Cost Issues With CT Regimens and Bevacizumab

Charles Fuchs, MD: Strategies to Increase RAS Testing

Charles Fuchs, MD: Impeding RAS Mutation Testing

Charles Fuchs, MD: Percentage of RAS Mutation Tests in Metastatic CRC

Charles Fuchs, MD: RAS Mutations and the Sequence of Therapies

Charles Fuchs, MD: Clinical Importance of RAS Mutations

Charles Fuchs, MD: RAS Mutations in Metastatic Colorectal Cancer

Tanios Bekaii-Saab, MD: Cost Issues With CT Regimens and Bevacizumab

Tanios Bekaii-Saab, MD: Strategies to Increase RAS Testing

Tanios Bekaii-Saab, MD: Impeding RAS Mutation Testing

Tanios Bekaii-Saab, MD: Percentage of RAS Mutation Tests in Metastatic CRC

Tanios Bekaii-Saab, MD: RAS Mutations and the Sequence of Therapies

Tanios Bekaii-Saab, MD: Clinical Importance of RAS Mutations

Tanios Bekaii-Saab, MD: RAS Mutations in Metastatic Colorectal Cancer

Tanios Bekaii-Saab, MD: Mutations in Colorectal Cancer

Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD: Case 2

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

FAQ: When and How to Discontinue Lenalidomide Maintenance in Multiple Myeloma

Intranasal NEO100 Meets Primary End Point in Recurrent IDH1-Mutant Glioma

With 4 Guideline-Preferred Options, CNS Activity Is Deciding Frontline ROS1+ NSCLC Therapy

Study Finds Genomic Profiling Turnaround Time Improves, but Delays Persist

FDA Does Not Approve 177Lu-Edotreotide for GEP-NETs